Effect of topical immunotherapy with squaric acid dibutylester for alopecia areata in Japanese patients.
Alopecia
Cohort study
Response rate
Severity
Topical immunotherapy
Journal
Allergology international : official journal of the Japanese Society of Allergology
ISSN: 1440-1592
Titre abrégé: Allergol Int
Pays: England
ID NLM: 9616296
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
19
06
2019
revised:
19
10
2019
accepted:
30
10
2019
pubmed:
27
11
2019
medline:
15
12
2020
entrez:
27
11
2019
Statut:
ppublish
Résumé
The Japanese guidelines for the treatment of alopecia areata list topical immunotherapies as a drug therapy for this condition. However, there is insufficient evidence of its efficacy to support this recommendation. Thus, we sought to clarify the effect of topical immunotherapy on the progression and severity of alopecia areata in Japanese patients. To evaluate the effect of topical immunotherapy with squaric acid dibutylester (SADBE) in alopecia areata patients, we performed a retrospective cohort study on 49 alopecia patients who had received topical immunotherapy with SADBE. Patients were evaluated by the change in alopecia severity at 6 and 12 months after the initiation of topical immunotherapy. The improvement rate was calculated by determination of the complete and partial responses rate to treatment with topical immunotherapy by application of SADBE. The improvement rate in all alopecia patients treated with SADBE topical immunotherapy was 57.8% (complete response; 11.1% and partial response; 46.7%). Topical immunotherapy with SADBE is an effective treatment for alopecia areata. Therefore, the current treatment recommendations for alopecia areata with topical immunotherapies are appropriate.
Sections du résumé
BACKGROUND
BACKGROUND
The Japanese guidelines for the treatment of alopecia areata list topical immunotherapies as a drug therapy for this condition. However, there is insufficient evidence of its efficacy to support this recommendation. Thus, we sought to clarify the effect of topical immunotherapy on the progression and severity of alopecia areata in Japanese patients.
METHODS
METHODS
To evaluate the effect of topical immunotherapy with squaric acid dibutylester (SADBE) in alopecia areata patients, we performed a retrospective cohort study on 49 alopecia patients who had received topical immunotherapy with SADBE. Patients were evaluated by the change in alopecia severity at 6 and 12 months after the initiation of topical immunotherapy. The improvement rate was calculated by determination of the complete and partial responses rate to treatment with topical immunotherapy by application of SADBE.
RESULTS
RESULTS
The improvement rate in all alopecia patients treated with SADBE topical immunotherapy was 57.8% (complete response; 11.1% and partial response; 46.7%).
CONCLUSIONS
CONCLUSIONS
Topical immunotherapy with SADBE is an effective treatment for alopecia areata. Therefore, the current treatment recommendations for alopecia areata with topical immunotherapies are appropriate.
Identifiants
pubmed: 31767273
pii: S1323-8930(19)30172-8
doi: 10.1016/j.alit.2019.10.008
pii:
doi:
Substances chimiques
Cyclobutanes
0
squaric acid diethyl ester
5231-87-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
274-278Informations de copyright
Copyright © 2019 Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.